Press release - Personnel change in the area of Medical Policies & Development
31.03.2021 | PDF | 231.46 KB
PD Dr. Ilona Funke, Head of Medical Policies & Development at the Hirslanden Group, will take over the position of Group General Manager Clinical Services at Mediclinic International plc, the parent company of Hirslanden, on 1 April 2021. She will thus have overall responsibility for the clinical strategy of the three divisions of the group.
Since taking over her current role in November 2019, Ilona Funke has had various interactions with Mediclinic International plc (MCI). The specialist in surgery and plastic surgery successfully contributes her in-depth medical expertise to cross-divisional projects, currently among other things on various pandemic-related topics. Ilona Funke is also involved in a large number of strategic projects for the Hirslanden Group.
Before her position as Head of Medical Policies & Development at the headquarters, Ilona Funke was head of the Clinical Systems division at the Klinik St. Anna for three years. Ilona Funke was able to significantly strengthen and improve the professionally excellent as well as personal treatment of patients, among other things by promoting interdisciplinary and interprofessional cooperation between the specialist departments. Before Ilona Funke joined the Hirslanden Group, she was head doctor for breast and plastic surgery for ten years and, for the last three years, also deputy director of an academic teaching hospital at the Ludwig Maximilians University (LMU) in Munich. Ilona Funke is also the co-founder and managing director of a biomedical spin-off from LMU and has an MBA in Health Care Management.
The Executive Committee would like to express its thanks to Ilona Funke for her excellent achievements and her great commitment to Hirslanden. “We congratulate Ilona Funke on her appointment as Group General Manager Clinical Services and wish her every success in her new position. In this key role, she will use her profound expertise as well as her skills as a facilitator to further develop the strategies on our clinical core competencies across divisions for the benefit of patients," says CEO Daniel Liedtke.
The Hirslanden Group operates 17 hospitals in 10 cantons, many of which have an emergency department. It also operates 4 outpatient surgical units, 17 radiology institutes and 5 radiotherapy institutes. Together with public and private cooperation partners, Hirslanden focuses on the continuum of care and the promoting of high-quality, responsible, personalised and efficiently integrated healthcare. The Group has 2 506 affiliated doctors and 10 417 employees, 498 of whom are permanently employed doctors. Hirslanden is the largest medical network in Switzerland. In the 2019/20 financial year, the Group generated turnover of CHF 1’804 million. As at 31.3.2020, the Group had treated 107’491 patients, amounting to a total of 471’717 inpatient days. In insurance terms, the patient mix consists of 49.2% basic, 29.3% semi-private, and 21.5% private insured patients.
Hirslanden is synonymous with first-class medical care provided by highly qualified medical specialists with many years of experience. As a system provider, the Group stands out from the rest of the market: interdisciplinary medical centres of expertise and specialised institutes enable it to offer the best possible individualised treatment, even in highly complex cases. The Hirslanden Group was formed in 1990 through the merger of several hospitals. Since 2007, it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.